![Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire](https://mms.businesswire.com/media/20200915005685/en/821174/4/Systems_Oncology_logo.jpg)
Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire
![Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice | Fierce Biotech Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice | Fierce Biotech](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1626856483/bayer-office-building-socialmedia-1200x630.jpg/bayer-office-building-socialmedia-1200x630.jpg?VersionId=NGzveud.1RCGIotCel_XiAXW8GJRa9pm)
Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice | Fierce Biotech
![Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire](https://mms.businesswire.com/media/20200915005685/en/821173/4/Bayer_Logo.jpg)
Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire
![Cancer compound originating from U of I scientists leads to major licensing deal | School of Molecular & Cellular Biology | UIUC Cancer compound originating from U of I scientists leads to major licensing deal | School of Molecular & Cellular Biology | UIUC](https://mcb.illinois.edu/sites/default/files/2022-05/erso%20molecule%20image.png)
Cancer compound originating from U of I scientists leads to major licensing deal | School of Molecular & Cellular Biology | UIUC
![Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire](https://mms.businesswire.com/media/20200915005685/en/821173/3/Bayer_Logo.jpg)
Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire
![Cancer Center at Illinois on X: "CCIL scientists developed a promising breast cancer treatment leading to a licensing agreement with @Bayer and @SystemsOncology. The compound, ERSO, has been shown to target & Cancer Center at Illinois on X: "CCIL scientists developed a promising breast cancer treatment leading to a licensing agreement with @Bayer and @SystemsOncology. The compound, ERSO, has been shown to target &](https://pbs.twimg.com/media/EjP4x0mUcAAco8Y.jpg:large)